INT Medical

Shanghai INT Medical Instruments Co., Ltd. (hereinafter referred to as "the Company") was established in 2006 and is a main board listed company on the Hong Kong Stock Exchange (Stock abbreviation: INT Medical, Stock code: HK1501). The Company holds a leading position in China-produced cardiovascular interventional devices and is one of the few medical device manufacturers in China with complete industrial capabilities including independent mold development, product R&D, equipment development, and autonomous sterilization. The Company has successively passed ISO13485, CE, and FDA certifications, and its products are exported to more than 70 countries and regions worldwide. The Company oversees 16 subsidiaries, each focusing on the R&D, production, and sales of innovative products in fields such as cardiovascular, peripheral, neurology, orthopedics, urology, ENT, exosome therapy, and ultrasound-focused non-invasive treatment. The Company adheres to the corporate culture of "Teamwork is the cornerstone of entrepreneurship, innovation is the source of development, and execution is the key to success," continuously enhancing its independent innovation capabilities and developing proprietary intellectual property products. As of December 31, 2023, the Company owns 73 domestically registered products, 36 CE-certified products, 18 FDA-certified products, 334 authorized patents, 208 pending patents, and 9 software copyrights. The Company has received numerous honors including being named a National Specialized, Focused, Unique, and Innovative "Little Giant" enterprise, a Shanghai Enterprise Technology Center, and a Shanghai Patent Demonstration Enterprise. It has also been awarded over 70 government project supports, such as the National/Shanghai Innovation Fund projects, the National Ministry of Science and Technology's Science and Technology Innovation and Entrepreneurship Talent Award, the National "Ten Thousand Talents Plan" Leading Scientific Entrepreneurship Talent Award, the Shanghai Strategic Emerging Industries Major Projects, the Shanghai Torch Program, the Shanghai Science and Technology Support Project, the Shanghai Major Industrialization Project, and the Shanghai Science and Technology Second Prize. The Company currently employs over 1,500 staff members, with its primary production base located in Jiading District, Shanghai. In the future, the Company will aim to become "a globally renowned interventional and implantable medical device group led by technological innovation" as its development vision, consistently upholding the development philosophy of "Innovation serves health, quality builds excellence," providing impetus to the development of China's medical device industry, and contributing to the global health cause!